2. Search Result
Search Result
Results for "

TRPC3

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Peptides

1

Recombinant Proteins

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111098
    GSK1702934A
    1 Publications Verification

    		 TRP Channel Cardiovascular Disease
    GSK1702934A is a selective TRPC3 agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3 .
    GSK1702934A
  • HY-19408
    Pyr10
    3 Publications Verification

    		 TRP Channel Others
    Pyr10 is a pyrazole derivative and a selective TRP cation 3 (TRPC3) inhibitor. Pyr10 inhibits Ca 2+ influx in carbachol-stimulated TRPC3-transfected HEK293 cells with an IC50 of 0.72 μM (IC50 of 13.08 μM for store operated Ca 2+ entry in BRL-2H3 cells). Pyr10 has the ability to distinguish between receptor-operated TRPC3 and native stromal interaction molecule 1 (STIM1)/Orai1 channels .
    Pyr10
  • HY-108465
    Pyr3
    5+ Cited Publications

    		 TRP Channel Others
    Pyr3 is a selective inhibitor of transient receptor potential canonical channel 3 (TRPC3), with an IC50 of 700 nM for TRPC3-mediated Ca 2+ influx.
    Pyr3
  • HY-RS15105
    TRPC3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TRPC3 Human Pre-designed siRNA Set A contains three designed siRNAs for TRPC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TRPC3 Human Pre-designed siRNA Set A
    TRPC3 Human Pre-designed siRNA Set A
  • HY-120818
    TRPC3/6-IN-3

    		TRP Channel Cardiovascular Disease
    TRPC3/6-IN-3 is a selective TRPC3/6 blocker. TRPC3/6-IN-3 can be used for the research of cardiovascular disease .
    TRPC3/6-IN-3
  • HY-147357
    TRPC3/6-IN-1

    		TRP Channel Cardiovascular Disease
    TRPC3/6-IN-1 is a potent selectivity blocker of the canonical transient receptor channels (TRPC3/6), has block potency for hTRPC3 and hTRPC6 with IC50 values of 1260 nM and 500 nM, respectively. TRPC3/6-IN-1 can be used for the research of chronic models of heart failure .
    TRPC3/6-IN-1
  • HY-153455
    TRPC3/6-IN-2

    		TRP Channel Metabolic Disease
    TRPC3/6-IN-2 is a potent TRPC3/6 inhibitor with IC50 values of 16 nM and 29.8 nM for TRPC3 and TRPC6, respectively .
    TRPC3/6-IN-2
  • HY-121519
    GSK2332255B

    		TRP Channel Cardiovascular Disease
    GSK2332255B is a potent, selective TRPC3 and TRPC6 antagonist with IC50s of 5 nM and 4 nM for rat TRPC3 and rat TRPC6. GSK2332255B shows ≥100-fold selectivity for TRPC3/6 over other calcium-permeable channels .
    GSK2332255B
  • HY-133528
    OptoBI-1

    		TRP Channel Neurological Disease
    OptoBI-1 is a photochromic TRPC3 agonist, which asts as a photopharmacological tool to control of neuronal firing .
    OptoBI-1
  • HY-161766
    L687

    		TRP Channel Cancer
    L687 is a potent activator of TRPC3/C6/C7 that can induce cellular uptake of oligonucleotides .
    L687
  • HY-138668
    JW-65

    		TRP Channel Cancer
    JW-65 (compound 20) is a TRPC3 inhibitor. JW-65 can be used in neurological and cardiovascular disease related research .
    JW-65
  • HY-111527
    PPZ2

    		Others Neurological Disease
    PPZ2 is a diacylglycerol (DAG)-activated TRPC3/TRPC6/TRPC7 channel activator with activity in promoting neuronal development and survival. PPZ2 activates recombinant TRPC3/TRPC6/TRPC7 channels in a dose-dependent manner without affecting other TRPC channels. PPZ2 elicits cation currents and calcium ion (Ca(2+)) influx in cultured central neurons. PPZ2 is able to induce BDNF-like neurite outgrowth and neuroprotection, an effect that disappears after TRPC3/TRPC6/TRPC7 knockdown or inhibition. PPZ2 also increases the activation of the calcium-dependent transcription factor cAMP response element binding protein. The effects of PPZ2 suggest that calcium signaling mediated by activation of DAG-activated TRPC channels plays an important role in its neurotrophic effects .
    PPZ2
  • HY-126424
    OptoDArG

    		Others Others
    OptoDArG is a photoswitchable probe that has the activity to recognize lipid-gated pores by controlling TRPC3 channels and can be used as a tool to study the lipid sensing mechanism of TRPC channels.
    OptoDArG
  • HY-12504
    Pyr6
    1 Publications Verification

    N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide

    		 TRP Channel Others
    Pyr6 is a selective inhibitor of TRPC3 with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).
    Pyr6
  • HY-162090
    TRPC antagonist 1

    		TRP Channel Cancer
    TRPC antagonist 1 (compound 15g) is a potent TRP channel (TRPC) antagonist with IC50s of 2.4 μM, 12.2 μM, 7.6 μM, 2.9 μM, and 3.4 μM for TRPC3, TRPC4, TRPC5, TPRC6, and TRPC7, respectively. TRPC antagonist 1 displays noteworthy anti-glioblastoma efficacy in vitro against U87 cell lines .
    TRPC antagonist 1
  • HY-P2141A
    TRV-120027 TFA
    3 Publications Verification

    		 Angiotensin Receptor Arrestin Cardiovascular Disease
    TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
    TRV-120027 TFA
  • HY-P2141
    TRV-120027
    3 Publications Verification

    		 Angiotensin Receptor Arrestin Cardiovascular Disease
    TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
    TRV-120027
  • HY-111925
    BI-749327
    Maximum Cited Publications
    12 Publications Verification

    		 TRP Channel Cardiovascular Disease
    BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC50s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7 .
    BI-749327
  • HY-101507
    Pico145
    5+ Cited Publications

    HC-608

    		 TRP Channel Cancer
    Pico145 (HC-608) is a remarkable inhibitor of TRPC1/4/5 channels, inhibits (−)-englerin A-activated TRPC4/TRPC5 channels, with IC50s of 0.349 and 1.3 nM in cells, and shows no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8 .
    Pico145

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: